AEON Biopharma, Inc. financial data

Symbol
AEON on NYSE
Industry
Pharmaceutical Preparations
Location
5 Park Plaza, Suite 1750, Irvine, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Priveterra Acquisition Corp. (to 7/24/2023)
Latest financial report
10-K - Q4 2024 - Mar 24, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 20.4 % -64.2%
Debt-to-equity -109 % -93.3%
Return On Equity -58.6 %
Return On Assets 1.06K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 10.5M shares -73.1%
Common Stock, Shares, Outstanding 556K shares +7.57%
Entity Public Float 17M USD +19.7%
Common Stock, Value, Issued 4K USD 0%
Weighted Average Number of Shares Outstanding, Basic 540K shares
Weighted Average Number of Shares Outstanding, Diluted 576K shares

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 14.2M USD
Operating Income (Loss) 73M USD
Nonoperating Income (Expense) -31M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 42M USD
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent 42M USD
Earnings Per Share, Basic 77.7 USD/shares
Earnings Per Share, Diluted 72.9 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 13K USD -99.7%
Assets, Current 1.59M USD -74.4%
Property, Plant and Equipment, Net 235K USD -29.2%
Operating Lease, Right-of-Use Asset 1.29M USD +392%
Other Assets, Noncurrent 29K USD 0%
Assets 3.14M USD -54.1%
Accounts Payable, Current 5.91M USD +74.4%
Employee-related Liabilities, Current 1.07M USD +13.3%
Liabilities, Current 14.1M USD +8.43%
Operating Lease, Liability, Noncurrent 1.15M USD
Liabilities 31.7M USD -80.2%
Retained Earnings (Accumulated Deficit) -432M USD +8.87%
Stockholders' Equity Attributable to Parent -153M USD +46.8%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -28.6M USD +81.3%
Liabilities and Equity 3.14M USD -54.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.6M USD +22.2%
Net Cash Provided by (Used in) Financing Activities 5M USD -16.7%
Net Cash Provided by (Used in) Investing Activities 260M USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 556K shares +7.57%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.6M USD +28.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 13K USD -99.7%
Deferred Tax Assets, Valuation Allowance 59.6M USD +10.3%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 61M USD +12.7%
Operating Lease, Liability 1.27M USD +355%
Lessee, Operating Lease, Liability, to be Paid 1.43M USD +388%
Property, Plant and Equipment, Gross 502K USD 0%
Operating Lease, Liability, Current 121K USD -56.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 297K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 175K USD -40.1%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 160K USD +1043%
Lessee, Operating Lease, Liability, to be Paid, Year Three 307K USD
Deferred Tax Assets, Operating Loss Carryforwards 36M USD +25.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 16.1M USD +9.85%
Lessee, Operating Lease, Liability, to be Paid, Year Four 318K USD
Operating Lease, Payments 319K USD
Additional Paid in Capital 32K USD 0%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 25K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 1.43M USD +831%
Share-based Payment Arrangement, Expense 1.6M USD -27.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%